Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: A double-blind randomised clinical trial

Thrombosis and Haemostasis

Volumn 113, Issue 5, 2015, Pages 1135-1144

  Knapen, Marjo H J ^a   Braam, Lavienja A J L M ^a   Drummen, Nadja E ^a   Bekers, Otto ^b   Hoeks, Arnold P G ^c   Vermeer, Cees ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Arterial stiffness; Carotid intima media thickness; Menaquinone 7; Pulse wave velocity; Stiffness index

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 6; MENAQUINONE; OSTEOCALCIN; PHYTOMENADIONE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; FARNOQUINONE; HEMOSTATIC AGENT; IL6 PROTEIN, HUMAN; SELE PROTEIN, HUMAN; TNF PROTEIN, HUMAN; VITAMIN MK 7;

ADULT; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTERY DILATATION; ARTICLE; BONE STRENGTH; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY REFERENCE INTAKE; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; YOUNG MODULUS; AGED; ANALOGS AND DERIVATIVES; ARTERIAL WALL THICKNESS; BLOOD; CAROTID ARTERY; DRUG EFFECTS; FEMORAL ARTERY; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; E-SELECTIN; FEMALE; FEMORAL ARTERY; GLYCOSYLATION END PRODUCTS, ADVANCED; HEALTHY VOLUNTEERS; HEMOSTATICS; HUMANS; INTERLEUKIN-6; MIDDLE AGED; POSTMENOPAUSE; PULSE WAVE ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR STIFFNESS; VITAMIN K 2;

EID: 84931263004     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-08-0675     Document Type: Article

References (49)

1. Laurent S, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–2605.
2. Mattace-Raso FU, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113: 657–663.
3. van Popele NM, et al. Aortic stiffness is associated with atherosclerosis of the coronary arteries in older adults: the Rotterdam Study. J Hypertension 2006; 24: 2371–2376.
4. Safar H, et al. Aortic pulse wave velocity, an independent marker of cardiovascular risk. Arch Mal Coeur Vaiss 2002; 95: 1215–1218.
5. Willum-Hansen T, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664–670.
6. Reference Values for Arterial Stiffness C. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors:’establishing normal and reference values’. Eur Heart J 2010; 31: 2338–2350.
7. Bode AS, et al. Determination of brachial artery stiffness prior to vascular access creation: reproducibility of pulse wave velocity assessment. NDT 2012; 27: 2370–2376.
8. Hayashi K, et al. Stiffness and elastic behavior of human intracranial and extracranial arteries. J Biomech 1980;13: 175–184.
9. Geleijnse JM, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr 2004; 134: 3100–3105.
10. Beulens JW, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009; 203: 489–493.
11. Gast GC, et al. A high menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis 2009; 19: 504–510.
12. Villines TC, et al. Vitamin K1 intake and coronary calcification. Coron Artery Dis 2005; 16: 199–203.
13. Erkkila AT, et al. Phylloquinone intake as a marker for coronary heart disease risk but not stroke in women. Eur J Clin Nutr 2005; 59: 196–204.
14. Erkkila AT, et al. Phylloquinone intake and risk of cardiovascular diseases in men. Nutr Metab Cardiovasc Dis 2007; 17: 58–62.
15. Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost 2008; 100: 530–547.
16. Braam LA, et al. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: a follow-up study. Thromb Haemost 2004; 91: 373–380.
17. Shea MK, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 2009; 89: 1799–1807.
18. Schurgers LJ, et al. Vitamin K–containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood 2007; 109: 3279–3283.
19. Cranenburg EC, et al. The Circulating Inactive Form of Matrix Gla Protein (ucMGP) as a Biomarker for Cardiovascular Calcification. J Vasc Res 2008; 45: 427–436.
20. Rennenberg RJ, et al. Calcium scores and matrix Gla protein levels: association with vitamin K status. Eur J Clin Invest 2010; 40: 344–349.
21. Schurgers LJ, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010; 5: 568–575.
22. Mayer O, Jr., et al. Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease. Atherosclerosis 2014; 235: 162–168.
23. Liabeuf S, et al. Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein. Cardiovasc Diabetol 2014; 13: 85.
24. Dalmeijer GW, et al. Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. J Nutr Biochem 2013; 24: 624–628.
25. Ueland T, et al. Circulating levels of non-phosphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chronic heart failure. Clin Sci 2011; 121: 119–127.
26. Shea MK, et al. Circulating uncarboxylated matrix gla protein is associated with vitamin k nutritional status, but not coronary artery calcium, in older adults. J Nutr 2011; 141: 1529–1534.
27. Dalmeijer GW, et al. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein. Atherosclerosis 2012; 225: 397–402.
28. Westenfeld R, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis 2012; 59: 186–195.
29. Theuwissen E, et al. Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects. Br J Nutr 2012; 108: 1652–1657.
30. van Bussel BC, et al. Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-year period. Hypertension 2011; 58: 588–595.
31. Reddi K, et al. Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (vitamin K) compounds. Cytokine 1995; 7: 287–290.
32. Shea MK, et al. Vitamin K, circulating cytokines, and bone mineral density in older men and women. Am J Clin Nutr 2008; 88: 356–363.
33. Shea MK, et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol 2008; 167: 313–320.
34. Juanola-Falgarona M, et al. Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk. Cardiovasc Diabetol 2013; 12: 7.
35. Kristensen M, et al. Six weeks phylloquinone supplementation produces undesirable effects on blood lipids with no changes in inflammatory and fibrinolytic markers in postmenopausal women. Eur J Nutr 2008; 47: 375–379.
36. Ebina K, et al. Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis. Mod Rheumatol 2013; 23: 1001–1007.
37. Knapen MH, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int 2013; 24: 2499–2507.
38. Shearer MJ, et al. Vitamin K nutrition, metabolism, and requirements: current concepts and future research. Adv Nutr 2012; 3: 182–195.
39. Koivistoinen T, et al. Arterial pulse wave velocity in relation to carotid intimamedia thickness, brachial flow-mediated dilation and carotid artery distensibility: the Cardiovascular Risk in Young Finns Study and the Health 2000 Survey. Atherosclerosis 2012; 220: 387–393.
40. Engelen L, et al. Reference intervals for common carotid intima-media thickness measured with echotracking: relation with risk factors. Eur Heart J 2013; 34: 2368–2380.
41. Shea MK, Holden RM. Vitamin K status and vascular calcification: evidence from observational and clinical studies. Adv Nutr 2012; 3: 158–165.
42. Luo G, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 385: 78–81.
43. Price PA, et al. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400–1407.
44. Liu Y.-P., et al. Inactive Matrix Gla Protein is causally related to health outcomes: a Mendelian randomization study in a Flemish population. Hypertension 2014; in press.
45. Cranenburg EC, et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost 2010; 104: 811–822.
46. Eastell R, et al. Cardiovascular disease and bone. Arch Biochem Biophys 2010; 503: 78–83.
47. den Uyl D, et al. (Sub) clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther 2011; 13: R5.
48. Katsuyama H, et al. Menaquinone-7 regulates gene expression in osteoblastic MC3T3E1 cells. Int J Mol Med 2007; 19: 279–284.
49. Vermeersch SJ, et al. Age and gender related patterns in carotid-femoral PWV and carotid and femoral stiffness in a large healthy, middle-aged population. J Hypertension 2008; 26: 1411–1419.